Possible Somatic Mosaicism of Novel FUS Variant in Familial Amyotrophic Lateral Sclerosis

Shin Hisahara, MD, PhD, Ayumi Nishiyama, MD, PhD, Emiko Tsuda, MD, PhD, Syuuichiro Suzuki, MD, PhD, Akihiro Matsumura, MD, PhD, Aki Ishikawa, MD, PhD, Akihiro Sakurai, MD, PhD, Ikuko N. Motoike, PhD, Masashi Aoki, MD, PhD, Yoko Aoki, MD, PhD, and Shun Shimohama, MD, PhD

Neurol Genet 2021;7:e552. doi:10.1212/NXG.0000000000000552

Fused-in-sarcoma (FUS) mutation is associated with a familial amyotrophic lateral sclerosis (fALS) characterized by early onset and rapid progression. Here, the authors describe a rare case of possible somatic mosaicism of a novel FUS variant for a fALS family with intrafamilial clinical variability.

Cases

Case 1

The index case (II-6, figure, A) was a woman who had gradual weight loss and gait disorder from age 44 years. Two years later, she could not walk without assistance. Neurologic examination at age 46 revealed tongue atrophy and fasciculation, together with weakness and fasciculation in her limbs and trunk. Pathologic reflexes were observed bilaterally. Needle EMG showed active and chronic neurologic changes in multiple regions, suggesting ALS. Enteral nutrition with percutaneous endoscopic gastrostomy were started at age 47, and artificial ventilation with tracheostomy at age 50.

Case 2

The son of the index case (III-5, figure, A) was born by full-term normal delivery. His psychomotor milestones were normal. At age 11 years, he had difficulty standing from a squatting position. At age 12, he was seen by a pediatrician because of his inability to walk. Neurologic examination indicated muscle weakness in his limbs. Increased deep tendon reflexes were observed. Muscle biopsy was performed twice, with results indicating neurogenic diseases including ALS rather than myopathies. He complained of respiratory distress 2 months later and required tracheostomy and artificial ventilation at 6 months after admission. Six months later, he was in a complete locked-in state. He died at the age of 33.

Whole exome analysis using a blood sample from Case 2 identified a novel heterozygous FUS variant (c. 1,542_1545delGGGT, p.Gly515Serfs13*) (figure, A and B). Surprisingly, it was difficult to detect the same variant in the blood sample of case 1 because of the low frequency of the mutant allele; only 1/30 reads counted using the Integrative Genomics Viewer (figure e-1, links.lww.com/NXG/A363). The targeted next generation sequencing (NGS) data from her peripheral blood and saliva showed repeatable low variant rates of 4/327 and 5/280 reads, respectively. Sanger sequencing confirmed that the mother had lower mutant allele fraction in blood than her son (figure, B). Furthermore, higher mutant allele fractions were detected in her hair and nail than blood and saliva (figure, B).
Discussion

We present a rare case of a possible somatic and germline mosaic variant in a patient with fALS. Sequencing confirmed lower mutant allele fraction in blood cells of the index case than her son. The index case also had different mutant allele fractions in various tissues. These observations indicate that she has a somatic variant of FUS across multiple tissues, which affects germline and somatic cells. This variant may have arisen before the 3 germ layers split, which could lead to mosaicism not restricted to the ectoderm, with lower but equivalent proportion of variant both in the mesoderm-derived blood and mesoderm- and ectoderm-derived saliva. Whether she had mosaicism in the CNS could not be investigated. However, given the higher variant fractions in tissues such as nail from the ectoderm system, a similar tendency may be found in neural tissues. Targeted deep sequencing in trio analysis revealed 3% of causative de novo mutations display postzygotic mosaicism.1

Her son showed more severe clinical course with juvenile onset and rapid progression. Recently, we found genetic linkage in 49.5% of a Japanese cohort of familial ALS.2 Most of the FUS-linked patients with fALS showed phenotype characterized by early onset, in contrast to patients with sporadic ALS.3 The variant p.G515Sfs13* is located in the highly conserved C terminal of FUS protein, where most of the FUS variants have been identified.4 The mutant protein has a truncated peptide from 515 to 526 amino acids, which coincides with the mutant terminal peptides affected by p.R495QfsX527 variant.4 The degree of FUS protein mislocalization from nucleus to cytoplasm by C-terminal deletion correlates with the severity of clinical phenotype.5 However, variable phenotypes of the same FUS variant have been observed.4

Somatic mosaicism in ALS is probably rare, but this possibility should be considered. Several studies indicated somatic variant in other neurodegenerative disorders such as Alzheimer’s disease.6 The clinical course of case 1 suggests that somatic
variant may have a milder phenotype depending on the extent of mosaicism. In ALS, repeat expansions of C9ORF72 exhibit both intrafamilial and somatic instability leading to mosaicism.\(^7\) In patients with intrafamilial variability or apparently sporadic disease, it may be important to suspect somatic mosaic variants during screening for candidate variants using high coverage NGS. Furthermore, variant analysis using multiple tissues other than peripheral blood may help identify low-level mosaicism. Additional studies including histopathology of these cases would contribute to elucidate the pathogenesis of ALS.

**Study Funding**

This research was supported by Initiative on Rare and Undiagnosed Diseases (IRUD) and JSPS KAKENHI Grant Number JP19K16997. This study was also supported in part by the Grant-in-Aid for Exploratory Research, grants from Smoking Research Foundation Grant Number 2049151 and by JSPS KAKENHI Grant Number 16H05279, JSPS KAKENHI Grant Number 17H07099, JSPS KAKENHI Grant Number 17K09783, JSPS KAKENHI Grant Number 15K19288, JSPS KAKENHI Grant Number 16K19776, and JSPS KAKENHI Grant Number 15K09840.

**Disclosure**

The authors report no relevant disclosures. Go to Neurology.org/NG for full disclosures.

**Publication History**

Received by Neurology: Genetics July 29, 2020. Accepted in final form November 9, 2020.

**References**


**Appendix**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syuuchi Hiro Suzuki, MD, PhD</td>
<td>Sapporo Medical University, Sapporo, Japan</td>
<td>Provided clinical information</td>
</tr>
<tr>
<td>Akihiro Matsumura, MD, PhD</td>
<td>Sapporo Medical University, Sapporo, Japan</td>
<td>Provided clinical information</td>
</tr>
<tr>
<td>Aki Ishikawa, MD, PhD</td>
<td>Sapporo Medical University, Sapporo, Japan</td>
<td>Performed genetic consultation</td>
</tr>
<tr>
<td>Akifumi Sakurai, MD, PhD</td>
<td>Sapporo Medical University, Sapporo, Japan</td>
<td>Performed genetic consultation, supervised the study</td>
</tr>
<tr>
<td>Ikuko N. Motoike, PhD</td>
<td>Tohoku Medical Megabank Organization, Sendai, Japan</td>
<td>Performed analysis and acquisition of data</td>
</tr>
<tr>
<td>Masashi Aoki, MD, PhD</td>
<td>Tohoku University, Sendai, Japan</td>
<td>Supervised the study and obtained funding</td>
</tr>
<tr>
<td>Yoko Aoki, MD, PhD</td>
<td>Tohoku University, Sendai, Japan</td>
<td>Supervised genomic analyses, and critically revised the manuscript</td>
</tr>
<tr>
<td>Shun Shimohama, MD, PhD</td>
<td>Sapporo Medical University, Sapporo, Japan</td>
<td>Supervised the study, critically revised the manuscript, and obtained funding</td>
</tr>
</tbody>
</table>

**Appendix Authors**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shin Hisahara, MD, PhD</td>
<td>Sapporo Medical University, Sapporo, Japan</td>
<td>Designed and conceptualized study and drafted the manuscript</td>
</tr>
<tr>
<td>Ayumi Nishiyama, MD, PhD</td>
<td>Tohoku University, Sendai, Japan</td>
<td>Performed analysis, interpreted the data, and drafted the manuscript</td>
</tr>
<tr>
<td>Emiko Tsuda, MD, PhD</td>
<td>Sapporo Shirakabai Hospital, Sapporo, Japan</td>
<td>Provided clinical information</td>
</tr>
</tbody>
</table>
Possible Somatic Mosaicism of Novel FUS Variant in Familial Amyotrophic Lateral Sclerosis
Neurol Genet 2021;7;
DOI 10.1212/NXG.0000000000000552

This information is current as of January 12, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://ng.neurology.org/content/7/1/e552.full.html

References
This article cites 7 articles, 1 of which you can access for free at:
http://ng.neurology.org/content/7/1/e552.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Clinical Neurology
http://ng.neurology.org/cgi/collection/all_clinical_neurology
All Genetics
http://ng.neurology.org/cgi/collection/all_genetics
Amyotrophic lateral sclerosis
http://ng.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis_

Permissions & Licensing
Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:
http://ng.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://ng.neurology.org/misc/addir.xhtml#reprintsus